SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors

Although clinical studies have evaluated several MEK1/2 inhibitors, it is unlikely that MEK1/2 inhibitors will be studied clinically. BRAF mutations have been proposed as a responder marker of MEK1/2 inhibitors in a preclinical study. However, current clinical approaches focusing on BRAF mutations h...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiga, Masaki, Nakayama, Ayako, Shikata, Yuki, Sasazawa, Yukiko, Murakami, Ryo, Nakanishi, Toshiyuki, Tashiro, Etsu, Imoto, Masaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313120/
https://www.ncbi.nlm.nih.gov/pubmed/25640451
http://dx.doi.org/10.1038/srep08155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313120/
https://www.ncbi.nlm.nih.gov/pubmed/25640451
http://dx.doi.org/10.1038/srep08155

Ejemplares similares